April 23, 2021
Company claims the treatment reduces the hours of supplemental oxygen in the patients Cadila Healthcare Limited (Zydus Cadila) has received Restricted Emergency Use Approval from the Drug Controller General of India (DCGI) for the use of ‘Virafin’, Pegylated Interferon alpha-2b (PegIFN) in treating moderate Covid-19 infection in adults.
Announcing the development, the company informed that the single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients.
“When administered early on during Covid, Virafin will help patients recover faster and avoid much of the complications,” it said.
Virafin will be available on the prescription of medical specialist for use in hospital/institutional set-up.
Zydus gets DCGI emergency use approval for Virafin to treat moderate COVID-19 cases
(PTI Photo)
Zydus Cadila on Friday announced that the company had received Restricted Emergency Use Approval from the Drug Controller General of India (DCGI) for the use of âVirafinâ, Pegylated Interferon alpha-2b (PegIFN) in treating moderate COVID-19 infection in adults.
A single-dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during COVID, Virafin will help patients recover faster and avoid much of the complications. Virafin will be available on the prescription of a medical specialist for use in hospital/institutional setup.
DGCI approves emergency use of Zydus s Virafin in treating moderate COVID-19 infection ANI | Updated: Apr 23, 2021 16:36 IST
By Joymala Bagchi
New Delhi [India], April 23 (ANI): Zydus Cadila received emergency use approval from the Drugs Controller General of India (DGCI) on Friday for the use of Virafin , Pegylated Interferon alpha-2b (PegIFN) in treating moderate COVID-19 infection in adults.
A single-dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during COVID-19, Virafin will help patients recover faster and avoid much of the complications, the company said.
In a release, Cadila Health highlighted that the drug has also shown efficacy against other viral infections.
Zydus s antiviral drug Virafin gets emergency approval to treat moderate Covid patients theprint.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theprint.in Daily Mail and Mail on Sunday newspapers.
(PTI Photo)
New Delhi: Zydus Cadila has received emergency use approval from the Drugs Controller General of India (DGCI) for the use of Virafin in treating moderate Covid-19 infection in adults.
A single-dose of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during COVID-19, Virafin will help patients recover faster and avoid much of the complications, the company said.
In a release, Cadila Health highlighted that the drug has also shown efficacy against other viral infections. Speaking on the development, Dr Sharvil Patel, Managing Director, Cadila Healthcare Limited, said, The fact that we are able to offer a therapy which significantly reduces the viral load when given early on can help in better disease management. It comes at a much-needed time for patients and we will continue to provide them access to critical therapies in this battle against COVID-19.